Philip Bonomi to Antibodies, Monoclonal
This is a "connection" page, showing publications Philip Bonomi has written about Antibodies, Monoclonal.
Connection Strength
0.897
-
Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol. 2006 Nov 20; 24(33):5253-8.
Score: 0.268
-
Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer. Cancer. 2015 Mar 15; 121(6):883-92.
Score: 0.116
-
Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer. Expert Rev Anticancer Ther. 2010 Oct; 10(10):1589-99.
Score: 0.088
-
Implications of key trials in advanced nonsmall cell lung cancer. Cancer. 2010 Mar 01; 116(5):1155-64.
Score: 0.084
-
Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol. 2009 Jul 10; 27(20):3284-9.
Score: 0.079
-
Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer. 2008 Jul; 61(1):82-90.
Score: 0.073
-
Current strategies in the management of lung cancer. Oncology (Williston Park). 2005 Nov; 19(13):1667-8.
Score: 0.062
-
Locally advanced NSCLC: current state of the art, treatment and future directions. J Natl Compr Canc Netw. 2004 Sep; 2 Suppl 2:S23-30.
Score: 0.057
-
The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial. J Thorac Oncol. 2016 Jun; 11(6):808-18.
Score: 0.032
-
Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. Clin Lung Cancer. 2009 Jul; 10(4):252-6.
Score: 0.020
-
Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol. 2007 Oct 20; 25(30):4743-50.
Score: 0.018